Parp Inhibitors for the Treatment of Ovarian Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|18|9|877-893

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.18, Iss.9, 2018-11, pp. : 877-893

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PARP Inhibitors: Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer

By Basu Bristi   Sandhu Shahneen K.   de Bono Johann S.  

Drugs, Vol. 72, Iss. 12, 2012-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite

Discussion of PARP inhibitors in cancer therapy

By Wielgos Monica   Yang Eddy S  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 755-766

Future Science

Access to resources Recommend Favorite

PARP inhibitors in cancer therapy: an update

By Papeo Gianluca   Casale Elena   Montagnoli Alessia   Cirla Alessandra  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 503-514

Informa Healthcare

Access to resources Recommend Favorite

Olaparib, PARP1 inhibitor in ovarian cancer

By Marchetti Claudia   Imperiale Ludovica   Gasparri Maria Luisa   Palaia Innocenza   Pignata Sandro   Boni Terenzio   Bellati Filippo   Benedetti Panici Pierluigi  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1575-1584

Informa Healthcare

Access to resources Recommend Favorite

Role of PARP Inhibitors in Cancer Biology and Therapy

By  

Current Medicinal Chemistry, Vol. 19, Iss. 23, 2012-08 ,pp. : 3907-3921

Bentham Science Publishers

Access to resources Recommend Favorite